Radiofrequency Exposure and Human Cancers: Elwood’s Response

I thank Hocking for his interest in my review (1). In regard to his own study (2), I put more emphasis on the incidence than the mortality results for several reasons. The interpretation of the mortality results is more complex, requiring control for confounding by prognostic factors (such as stage at diagnosis and precise age) as well as by risk factors for incidence. The difference between the relative risks for incidence and for mortality is not statistically significant, and of course the two results are not independent. The incidence results are also more useful because they can be compared with those of another study. The discussion in the paper by Hocking et al. (2) is almost all on the incidence relationship. The suggestion that radiofrequency radiation (RFR) exposure is related to adverse survival is a new hypothesis generated from these results and, as far as I know, has not been assessed in other studies.

The comparison of the two studies of childhood leukemia in Sydney, Australia (2–4), involves a comparison of concepts. In his letter, Hocking claims that the original hypothesis for these studies was that the leukemia rate in the three areas close to the TV towers would be different from the rate in the six areas farther away; as stated in my review (1), his statistical analysis depends on this comparison. However, in my opinion, the original hypothesis is epidemiological—whether there is an increased cancer incidence (and mortality) in children exposed to RFR from TV towers; this is given as the objective in the first paper by Hocking et al. (2). The use of a statistical design that compares two sets of areas is one way to assess this. This approach is not unreasonable but ignores the information provided by the comparison of each individual area. Such data are relevant to the assessment of the consistency of any association, which is an important aspect in assessing causality. I was surprised that the results by individual municipality, which Hocking et al. had available, were not given in the original paper (4), as I believe they affect the interpretation. The subsequent analysis showed that the excess was seen in only one of the three areas close to the TV towers (3). Because of statistical variability, this does not rule out the general association seen by Hocking et al., but it shows inconsistency and weakens the argument that the association seen is caused by RFR from the TV towers rather than from any other cause.

In the Polish military study (5), the published report states that information on possible carcinogenic factors and RFR exposure was available for cancer cases from hospital records, in addition to data from other sources available for all personnel. This raises the possibility of systematic bias, as some information on exposure is available only for affected subjects. This potential bias has been noted independently in another detailed epidemiologic review (6). In regard to the U.S. Navy study (7), Hocking emphasizes the major weakness of the study, which I have noted. I agree that this study is very limited in exposure information.

In the case–control study of brain cancers, Thomas et al. (8) found a significant excess risk in electronics workers with no exposure to RFR, and no excess risk in those exposed to RFR who were not electronics workers. There was an increased risk in electronics workers who were also exposed to RFR, but this risk was lower than the risks for all electronics workers. Although this may be consistent with some complex promotional effect, the more parsimonious explanation is that the increased risk in electronics workers is due to some exposure other than RFR.

In his letter, Hocking refers to a New Zealand environment court case (9) that concerned a proposed Telecom cell phone transmitter site near a school. I appeared as an expert witness for Telecom, and he appeared as a witness for the school. My published review (1) was developed at the same time as my written evidence, but was not submitted until after the case in order to benefit from legal review as well as from scientific peer review. The legal hearing has resulted in a detailed judgment in favor of Telecom (9). In his judgment, Judge Jackson commented on the several expert witness submissions. He noted that “Elwood’s evidence was carefully constructed and balanced” (9).

In summary, although the points raised by Hocking are worthy of note, I do not agree that any of them represent “important omissions” in my review paper.

J. Mark Elwood
Department of Social and Preventive Medicine, University of Otago Dunedin, New Zealand
E-mail: melwood@gandalf.otago.ac.nz

REFERENCES AND NOTES

1. Elwood JM. A critical review of epidemiologic studies of radiofrequency exposure and human cancers. Environ Health Perspect 107(suppl 1):155–168 (1999).

2. Hocking B, Gordon IR, Brain HL, Hattiefe GE. Cancer incidence and mortality and proximity to TV towers. Med J Aust 165:601–605 (1996).

3. McKenzie DR, Yin Y, Morrell S. Childhood incidence of acute lymphoblastic leukemia and exposure to broadcast radiation in Sydney—a second look. Aust N Z J Public Health 22:360–367 (1998).

4. Hocking B, Gordon I, Hattifed GE. Childhood leukemia and TV towers revisited (Letter). Aust N Z J Public Health 23:104–105 (1999).

5. Szmigielski S. Cancer morbidity in subjects occupationally exposed to high frequency (radiofrequency and microwave) electromagnetic radiation. Sci Total Environ 190–191 (1998).

6. Bergqvist U. Review of epidemiological studies. In: Mobile Communications Safety (Kuster N, Balzano D, Lin JC, eds). London-Chapman & Hall, 1997:147–170.

7. Robinson CD, Silverman C, Jablons E. Effects upon health of occupational exposure to microwave radiation (radar). Am J Epidemiol 112:39–52 (1980).

8. Thomas ML, Stolley PD, Stemhagen A, Fontham ET, Bleeker ML, Stawat PA, Hoover RN. Brain tumor mortality risk among men with electrical and electronics jobs: a case–control study. J Natl Cancer Inst 79:233–238 (1987).

9. Shirley Primary School v. Telecom Mobile Communications Ltd. Case no C138/98. Environment Court, Christchurch, New Zealand, 14 December 1998. NZRMA (New Zealand Resources Management Act) 66–144, 1999.

Comments on “What Is a Tumor Promoter?”

In the August issue of Environmental Health Perspectives, Raymond Tennant (1), shared his perspective on how the identification of tumor promotion relates to the assessment of human health risk from environmental carcinogens.

I would like to reply to several of his statements. Although a complete reanalysis of his perspective is beyond this letter, I recommend additional reading (2–6). My comments are based on looking at the multistep, multimechanism process of carcinogenesis from a completely different paradigm, based on different assumptions.

Tennant (1) states that the role of the tumor-promoting agents has not been so specifically defined, even in the most well-studied mouse skin model.

It has been known for over 20 years that a testable hypothesis exists, based on a specific cellular mechanism; this hypothesis is supported by data derived from molecular oncological, biochemical, cellular, and now knockout mouse data (2,7). This mechanistic model, namely, the reversible inhibition of gap junctional intercellular communication (GJIC), is as complete, if not more so, than our detailed mechanistic understanding of “initiation,” which is assumed to be related to DNA damage and mutagenesis.
Tennant (1) stated that “...few, if any, DNA reactive or genotoxic substances are only tumor initiators.” Here, an assumption is being made that the DNA reactive or genotoxic substance [determined in an imperfect assay, such as the Ames test, sister chromatid exchange, thymidine kinase minus, hypoxanthine–guanine phosphoribosyltransferase, comet, micronucleus, and unscheduled DNA synthesis assays (8–11)] is, in fact, genotoxic. Even if an agent can damage DNA and lead to a mutation, the agent can cause cell death at significant exposure. Cell death can then lead to compensatory hyperplasia of the surviving cells. In addition, not all cytotoxic agents or hyperplastic-inducing conditions (burned tissue, surgery, etc.) damage DNA or cause mutations. There is an argument that these hyperplastic conditions cause mutations indirectly by causing surviving cells with nonlethal DNA lesions to have mutations fixed by DNA replication. Although in principle this is possible, it does not explain the fact that animals can be exposed to DNA-damaging agents, but promoted months later, after the DNA has been repaired. In addition, Tennant ignored the fact that spontaneously initiated cells exist in all organisms. Therefore, an agent that kills cells or acts as a mitogen, but is not a mutagen, could promote a previously existing spontaneously initiated cell. This could provide an alternative explanation to Tennant’s statement that long-term repetitive treatment with either DNA reactive or nonreactive substances can result in the initiation/promotion and progression of tumors. The fact that “for the vast majority of substances that are carcinogenic, repetitive exposures are required,” supports my contention that most of the so-called carcinogens (tested at high doses and for long periods of time) are, in fact, not true mutagens. Most are nongenotoxic, epigenetic substances. These substances are false positives in insensitive genotoxic assays or because the artifacts are ignored in these assays; this leads to the substances being misidentified as mutagens (8–11).

Tennant’s (1) third assumption is that initiation or induction of mutations occurs in “appropriate target cells.” Although I agree that carcinogenesis is the result of a small population of target cells being susceptible to neoplastic transformation (the pluripotent stem cells) (7,12), this has implications related to the necessity of some chemicals to be metabolized into electrophiles in order to damage DNA and induce mutations. When a rat is fed a chemical and a biochemist/molecular biologist grinds up a liver, extracts DNA, and searches for DNA lesions, he/she will find them. However, the hepatocytes (those cells with the drug-metabolizing enzymes) make up the greater portion of the DNA being analyzed. Only a few of the cells in the liver are the target or stem cells. Therefore, extrapolating from the exquisite molecular analyses of DNA lesions from nontarget cells to the tumor in the animal fed a chemical does not prove the chemical caused the mutation in an oncogene/tumor suppressor gene found in the rat tumor.

Tennant did not mention the hypothesis of GJC inhibition of tumor promotion. This hypothesis is based on the operational observation of the action of promoters in vitro, namely, promoters must be given after the initiation (hours, days, weeks, months, or in the case of humans, presumably years), consistently exceeding no-effect or threshold levels for extended periods. The early steps of promotion are reversible or interruptible. This cannot be explained by any mutagenic or irreversible process ascribed to initiators. Mutagenic events are, for practical purposes, irreversible. Promoters must lead to the clonal multiplication of the single initiated cell. This clonal expansion of initiated cells is the result of both a mitotic process due to an increase in the birth of new cells and the prevention of the death of initiated cells [inhibition of apoptosis (13)]. Normal quiescent or G0 cells are contact inhibited (14). Tumor promoters release cells from contact inhibition by involving the inhibition of GJC (13).

I take issue with Tennant’s statement (1) that

...there is no information such as chemical structure or in vitro effects to reliably predict potential non-DNA reactive carcinogens.

There are many papers [including studies of DDT, dieldrin, polychlorinated biphenyls, polychlorinated biphenyls, dinitrofluorobenzene, pentachlorophenol, etc. (16–18)] that predicted the tumor-promoting activity in vitro using the GJC assay before testing in vivo. Moreover, more recent papers have, in fact, shown structure–function relationships that correlate inhibition of GJC and tumor promotion (19–21).

Finally, I have a few comments related to the use of genetically modified mice and the DNA microarray technology. The connexin 32 knockout mouse may be the best model to search for tumor initiators of the rat liver because the mouse is a constitutive promoter (22) and because it has lost one of its tumor-suppressing genes. The use of DNA microarray technology to identify genes associated with non-DNA reactive carcinogens may be likenesses to closing the barn door after the horses have escaped. Some tumor-promoting chemicals can inhibit GJC very early (minutes), induce signal transduction, posttranslationally modify proteins (p53), alter gene expression, induce DNA synthesis, and lead to cell proliferation in the few target cells. Studying gene expression profiles in normal tissues (with few stem cells, more progenitor cells, and many terminally differentiated cells, all in different stages of the cell cycle and all expressing different genes, and a few apoptotic cells) and comparing treated or diseased tissues (with each cell type in different stages of the cell cycle and with different reactions to a given chemical) will generate bewildering patterns of gene expression, most of which will not reflect what goes on in the few target cells.

James E. Trosko
Department of Pediatrics and Human Development
Michigan State University
East Lansing, Michigan
E-mail: trosko@pilot.msu.edu

REFERENCES AND NOTES
1. Tennant R. What is a tumor promoter? [Editorial]. Environ Health Perspect 107:A390–A391 (1999).
2. Trosko JE, Ruch R. Cell-cell communication in carcinogenesis. Front Biosci (Online) 3:208–238 (1998) Available at http://www.bioscience.org/1998/v3/d/trosko/last.htm [cited 15 October 1999].
3. Trosko JE, Chang CC, Muddhak BV, Dupont E. Inter cellular communication: a paradigm for the interpretation of the initiation/promotion/progress model of carcinogenesis. In: Chemical Induction of Cancer: Modulation and Combination Effects (Arcos JC, ed). Boston, MA: Birkhauser, 1996:205–225.
4. Trosko JE, Chang CC, Medcalf A. Mechanisms of tumor promotion, potential role of intercellular communication. Cancer Invest 15:511–526 (1980).
5. Trosko JE. Hierarchical and cybernetic nature of biologic systems and their relevance to homeostatic adaptation to low-level exposures to oxidative stress-inducing agents. Environ Health Perspect 106(suppl 1):331–339 (1998).
6. Trosko JE, Chang CC, Upham B, Wilson M. Epigenetic toxicology as toxicant-induced changes in intracellular sig nalling leading to altered gap junctional intercellular communication. Toxicol Lett 102–103:71–78 (1998).
7. Trosko JE, Chang CC, Muddhak BV, Dupont E. Oncogenes, tumor suppressor genes and intercellular communication in the oncogene as partially blocked/ongoing hypothesis. In: New Frontiers in Cancer Causation (Iversen DH, ed). Washington, DC: Taylor & Francis, 1993:181–197.
8. Trosko JE. A failed paradigm: carcinogenesis is more than mutagenesis. Mutagenesis 3:363–366 (1988).
9. Trosko JE. Towards understanding carcinogenic hazards: a crisis in paradigms. J Am Coll Toxicol 8:1121–1123 (1989).
10. Trosko JE, Chang CC. The role of inhibited intercellular communication in carcinogenesis: implications for risk assessment from exposure to chemicals. In: Biologically Based Methods for Cancer Risk Assessment (Travers CC, ed). New York: Plenum Press, 1989:165–179.
11. Trosko JE. Challenge to the simple paradigm that ‘carcino gens’ are ‘mutagens’ and to the use of in vivo and in vitro assays used to test the paradigm. Mutat Res 297:245–249 (1997).
12. Trosko JE, Chang CC, Muddhak BV. Cell-cell communication: relationship of stem cells to the carcinogenic process. In: Mouse Liver Carcinogenesis: Mechanisms and Species Comparisons (Stevenson DE, Popp JA, Ward JM, McClain RM, Slaga TJ, Pitot HC, eds). New York: Alan R. Liss, 1990:259–276.
13. Bursch W, Oberhammer F, Schulte-Hermmann R. Cell death by apoptosis and its protective role against disease. Trends Pharm Sci 13:245–251 (1992).
14. Eagle H. Growth regulatory effects of cellular interaction. Nat Med Sci 1:1220–1223 (1981).
15. Yotti LP, Chang CC, Trosko JE. Elimination of metabolic cooperation in Chinese hamster cells by a tumor promoter. Science 206:1089–1091 (1979).

A 598
Volume 107, Number 12, December 1999 • Environmental Health Perspectives
Tumor Promoters: Tennant’s Response

Trosko indeed presents an alternative and valid position on the nature of tumor promotion. It is certainly true that disrupted intracellular communication is an important component in the promotion and development of tumors and may be another pathway by which repetitive exposure to nongenotoxic carcinogens and genotoxic carcinogens results in altered heritable cell phenotypes. The editorial in EHP (1) was not meant to be an exhaustive catalog of all of the various mechanisms by which nongenotoxic carcinogenesis can occur. It is clear that intercellular and intracellular signaling via endocrine, exocrine, paracrine, and autocrine pathways is critical in maintaining phenotypic stability. Evidence also suggests that when gap junctional intracellular communication pathways are disrupted, the frequent consequence is altered gene expression. Preliminary experiments (2) do not suggest that exposure of skin to nongenotoxic carcinogens or to a tumor promoter results in a bewildering pattern of changes in gene expression. We believe that it is plausible that analysis of time-dependent changes in the pattern of gene expression will provide an understanding of cell-signaling pathways that are altered by chemical exposure. It may also result in the recognition of biomarkers of critical events in the neoplastic process that will include disrupted gap junctional communication.

REFERENCES

1. Tennant R. What is a tumor promoter? [Editorial]. Environ Health Perspect 107:A290–A291 (1999).
2. Tennant R, et al. Unpublished data.